Research Paper Volume 15, Issue 22 pp 13452—13470

Figure 3. PLB alleviated TMJOA progression and cartilage degeneration in the rat UAC model. (A) Schematic model of the time course for establishment of UAC model of TMJOA rat treated with PLB by articular injection. (B) Representative H&E and Safranin O/fast green staining of control and UAC-induced TMJOA rat treated with/without different PLB (0.5, 1, 2 mg/kg). Scale bars, 200 μm. (C) Osteoarthritis Research Society International (OARSI) score evaluated based on Safranin O/fast green staining. n = 3. (D) Representative immunofluorescence staining of Col2α1, MMP-13 and GPX-4. Arrow heads indicated positive cells. n = 3. Scale bars, 50 μm. (E–G) Quantitative analysis of immunofluorescence staining of Col2α1, MMP-13 and GPX-4. (H) Representative Micro-CT of control and UAC-induced TMJOA rat treated with/without PLB. (I) Quantitative analysis of subchondral bone parameters of control and UAC-induced TMJOA rat treated with/without PLB. (All quantified data are shown as mean ± SEM; #p < 0.05, ##p < 0.01, *p < 0.05, **p < 0.01, by one-way ANOVA followed by the Tukey-Kramer test, #: CON vs UAC, *: UAC vs UAC+PLB).